Imidazoquinoxaline compounds as immunomodulators

Abstract

The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).

What is claimed is: 
     
         1 . A compound of Formula (I): 
       
         
           
           
               
               
           
         
         wherein: 
         R 1  is selected from the group consisting of hydrogen; 
         R 2  is selected from the group consisting of hydrogen, C 2 -C 12  alkyl, substituted C 2 -C 12  alkyl, C 2 -C 12  alkenyl, substituted C 2 -C 12  alkenyl, C 2 -C 12  alkynyl, substituted C 2 -C 12  alkynyl, C 3 -C 12  cycloalkyl, substituted C 3 -C 12  cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, hydroxy, hydroxyalkyl, halo, haloalkyl, amino, —OR 3 , —N(R 3 )(R 4 ), —NR 3 C(═O)R 4 , —NR 3 S(═O) p R 4 , —NR 3 C(═O)NR 4 R 5 , —NR 3 S(═O) p NR 4 R 5 , —C(═O)R 4 , —S(═O) p R 4 , —C(═O)NR 3 R 4 , —S(═O) p NR 3 R 4  and —C(═O)OR 4 ; 
         R 3 , R 4  and R 5  are each independently selected from the group consisting of hydrogen, C 1 -C 12  alkyl, substituted C 1 -C 12  alkyl, C 2 -C 12  alkynyl, substituted C 2 -C 12  alkynyl, C 2 -C 12  alkenyl, substituted C 2 -C 12  alkenyl, C 3 -C 12  cycloalkyl, substituted C 3 -C 12  cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, hydroxy, hydroxyalkyl, halo and haloalkyl; 
         R 6  is selected from the group consisting of hydrogen, halogen, hydroxy, —OR 3 , —N(R 3 )(R 4 ), C 1-3  haloalkyl, —O—C 1-3  haloalkyl, C 1-3  perhaloalkyl, —O—C 1-3  perhaloalkyl, C 1-3  hydroxyalkyl, —O—C 1-3  hydroxyalkyl, CN, —(CH 2 ) q C(═O)R 7 , —O—(CH 2 ) q C(═O)R 7 , —(CH 2 ) q N(R 8 )(R 9 ), —S—C 1-3  alkyl, —S(═O) 2 —R 10  and —S(═O) 2 N(R 8 )(R 9 ); 
         q is 0, 1, 2 or 3; 
         R 7  is selected from hydrogen, hydroxy, C 1-3  alkyl or C 1-3  alkoxy; and 
         R 8 , R 9  and R 10  are each independently hydrogen or C 1-3  alkyl; 
         provided that R 1 , R 2  and R 6  are not simultaneously hydrogen; and 
         if R 1  and R 6  are both H, R 2  is not butyl; 
         or a pharmaceutically acceptable salt thereof; a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. 
       
     
     
         2 . A compound of  claim 1 , wherein R 2  is hydrogen, C 2 -C 12  alkyl, substituted C 2 -C 12  alkyl, C 2 -C 12  alkenyl, substituted C 2 -C 12  alkenyl, or hydroxyalkyl. 
     
     
         3 . A compound of  claim 1 , wherein R 6  is hydrogen, —OR 3  or —N(R 3 )(R 4 ). 
     
     
         4 . A method of inducing an immune response in a subject, comprising:
 administering a compound of  claim 1  to the subject in an amount sufficient to induce an immune response in the subject.   
     
     
         5 . The method of  claim 4 , wherein the subject is suffering from a microbial infection. 
     
     
         6 . The method of  claim 4 , wherein the subject is suffering from a viral infection. 
     
     
         7 . The method of  claim 4 , wherein the subject is suffering from abnormal cellular proliferation or cancer. 
     
     
         8 . The method of  claim 4 , wherein the subject is suffering from allergic diseases. 
     
     
         9 . The method of  claim 4 , wherein the subject is suffering from asthma. 
     
     
         10 . The method of  claim 4 , wherein the subject is suffering from precancerous lesions, wherein the precancerous lesions are actinic keratosis. 
     
     
         11 . The method of  claim 4  wherein the compound is administered topically. 
     
     
         12 . A pharmaceutical composition, comprising: the compound of  claim 1  and a pharmaceutically acceptable excipient. 
     
     
         13 . A method of enhancing the immune response to an antigen in a subject, comprising: administering to the subject a composition comprising a compound of  claim 1  and an antigen, wherein the immune response to the antigen in the subject is enhanced. 
     
     
         14 . A composition comprising the compound of  claim 1  and an additional immunogenic composition or an antigen. 
     
     
         15 . The composition of  claim 14 , further comprising an adjuvant, wherein the adjuvant is MF59. 
     
     
         16 . The composition of  claim 14 , further comprising poly(lactide-co-glycolide) (PLG). 
     
     
         17 . The composition of  claim 14 , wherein the antigen is a bacterial antigen or a viral antigen. 
     
     
         18 . The composition of  claim 17 , wherein the antigen is a viral antigen from a virus selected from the group consisting of Hepatitis C virus, Human Immunodeficiency virus, Hepatitis B virus, Human Papilloma virus and Influenza virus. 
     
     
         19 . The composition of  claim 17 , wherein the antigen is an influenza antigen, and wherein the influenza antigen comprises hemagglutinin and/or neuraminidase surface proteins. 
     
     
         20 . An immunogenic composition comprising an antigen and the compound of  claim 1  effective to stimulate a cell mediated immune response to said antigen.